A5103084165- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- SARS-CoV-2 detection and testing
- Respiratory viral infections research
- Long-Term Effects of COVID-19
- Mosquito-borne diseases and control
- Influenza Virus Research Studies
- Blood Pressure and Hypertension Studies
- Sirtuins and Resveratrol in Medicine
- Animal Virus Infections Studies
- HIV/AIDS drug development and treatment
- Cardiac, Anesthesia and Surgical Outcomes
- HIV Research and Treatment
- Medicinal Plants and Neuroprotection
- Smart Grid Energy Management
- Coronary Interventions and Diagnostics
- IL-33, ST2, and ILC Pathways
- Cardiac Imaging and Diagnostics
- Sodium Intake and Health
- Malaria Research and Control
- interferon and immune responses
- Energy and Environment Impacts
- Pain Management and Opioid Use
- Parasites and Host Interactions
- Pharmaceutical Practices and Patient Outcomes
Georgia State University
2020-2025
Intellectual Ventures (United States)
2015-2018
Bellevue Hospital Center
2015-2016
American Pharmacists Association
2014
Royal University Hospital
2012
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection can cause neurological disease in humans, but little is known about the pathogenesis of SARS-CoV-2 central nervous system (CNS). Herein, using K18-hACE2 mice, we demonstrate that neuroinvasion and encephalitis associated with mortality these mice. Intranasal mice 105 plaque-forming units resulted 100% by day 6 after infection. The highest virus titers lungs were observed on 3 declined days 5 By contrast, very high levels...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the current pandemic, resulting in millions of deaths worldwide. Increasingly contagious variants concern (VoC) have fueled recurring global infection waves. A major question is relative severity disease by previous and currently circulating SARS-CoV-2. In this study, we evaluated pathogenesis SARS-CoV-2 human ACE-2-expressing (K18-hACE2) mice. Eight-week-old K18-hACE2 mice were inoculated intranasally with a...
Abstract Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection can cause neurological disease in humans, but little is known about the pathogenesis of SARS-CoV-2 central nervous system. Herein, using K18-hACE2 mice, we demonstrate that neuroinvasion and encephalitis associated with mortality these mice. Intranasal mice 10 5 plaque-forming units resulted 100% by day 6 after infection. The highest virus titers lungs were observed at 3 declined days In contrast, very high...
Transgenic mice expressing human angiotensin-converting enzyme 2 under the cytokeratin 18 promoter (K18-hACE2) have been extensively used to investigate pathogenesis and tissue tropism of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. Neuroinvasion replication SARS-CoV-2 within central nervous system (CNS) K18-hACE2 is associated with increased mortality; although, mechanisms by which this occurs remain unclear. In study, we generated primary neuronal cultures from...
Medication information sheetsImmunodeficiency Clinic, Toronto General Hospital www.hivclinic.ca/main/drugs_fact.html CATIE (formerly known as Canadian AIDS Information Exchange) www.catie.ca/en/fact-
Neurological manifestations are a significant complication of coronavirus disease 2019 (COVID-19), but the underlying mechanisms yet to be understood. Recently, severe acute respiratory syndrome 2 (SARS-CoV-2)-induced neuroinvasion and encephalitis were observed in K18-hACE2 mice, leading mortality. Our goal this study was gain insights into molecular pathogenesis neurological mouse model. To analyze differentially expressed genes (DEGs) brains mice following SARS-CoV-2 infection, we...
Despite compelling evidence that modern housing protects against malaria, houses in endemic areas are still commonly porous to mosquitoes. The protective efficacy of four prototype screened doors and two windows designs mosquito house entry, their impact on indoor climate, as well use, durability acceptability was assessed a Gambian village. A baseline survey collected data all the discrete household units, each consisting front back room, were selected randomly allocated study arms. Each...
The emergence of new severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants concern pose a major threat to public health, due possible enhanced virulence, transmissibility and immune escape. These may also adapt hosts, in part through mutations the spike protein. In this study, we evaluated infectivity pathogenicity SARS-CoV-2 wild-type C57BL/6 mice. Six-week-old mice were inoculated intranasally with representative virus from original B.1 lineage, or emerging B.1.1.7 B.1.351...
Widespread and rapidly evolving SARS-CoV-2 posed an unprecedented challenge to vaccine developers. GeoVax has designed a multiantigen vaccine, designated GEO-CM02 based on Modified Vaccinia Virus (MVA) vector that expresses spike (S), membrane (M), envelope (E) antigens. This experimental was tested in the hACE2 transgenic mouse model assess immunogenicity efficacy. Administration of two-dose regimen elicited high levels neutralizing antibodies provided complete protection, effectively...
SARS-CoV-2 can cause severe lung damage due to uncontrolled viral replication or/and excessive inflammation. New variants of concern (VOCs) have raised additional concerns disparate pathogenicity and possible enhanced virulence. Herein, using RNA sequencing, we performed a comparative transcriptomic analysis following infection with major VOCs. We evaluated the transcriptional changes induced in lungs K18-hACE2 mice ancestral B.1 lineage (Wuhan), B.1.1.7 (Alpha), B.1.351 (Beta), B.1.617.2...
Summary SARS-COV-2 has recently emerged as a new public health threat. Herein, we report that the FDA-approved gold drug, auranofin, inhibits replication in human cells at low micro molar concentration. Treatment of with auranofin resulted 95% reduction viral RNA 48 hours after infection. Auranofin treatment dramatically reduced expression SARS-COV-2-induced cytokines cells. These data indicate could be useful drug to limit SARS-CoV-2 infection and associated lung injury due its anti-viral,...
Several approaches have produced an effective vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since millions of people are exposed to influenza virus and SARS-CoV-2, it is great interest develop a two-in-one that will be able protect infection both viruses. We developed hybrid for SARS-CoV-2 viruses using virus-like particles (VLP) incorporated by protein transfer with glycosylphosphatidylinositol (GPI)-anchored RBD fused GM-CSF as adjuvant. GPI-RBD-GM-CSF...
Owing to their continuous evolution, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) display disparate pathogenicity in mouse models. Omicron and its sublineages have been dominant worldwide. Compared pre-Omicron VOCs, early subvariants reportedly cause attenuated disease human ACE-2-expressing mice (K18-hACE-2). In late 2022, the frequency subvariant XBB.1.5 rapidly increased it progressively replaced other circulating strains. The emergence new...
Abstract The emergence of new severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants concern poses a major threat to the public health due possible enhanced virulence, transmissibility and immune escape. These may also adapt hosts in part through mutations spike protein. In this study, we evaluated infectivity pathogenicity SARS-CoV-2 wild-type C57BL/6 mice. Six-week-old mice were inoculated intranasally with representative virus from original B.1 lineage or emerging B.1.1.7...
Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a pandemic resulting in millions of deaths worldwide. Increasingly contagious variants concern (VoC) have fueled recurring global infection waves. A major question is the relative severity disease by previous and currently circulating SARS-CoV-2. In this study, we evaluated pathogenesis SARS-CoV-2 human ACE-2-expressing (K18-hACE2) mice. Eight-week-old K18-hACE2 mice were inoculated intranasally with...
In an effort to combat the spread of Ebola in West Africa, phase II/III clinical trials vaccines developed by Merck/Newlink Genetics and GSK were expedited. As a result, normal vaccine efficacy as function temperature tests have yet be conducted, leaving requirements -60C -80C, significantly colder than EPI 2-8C. The held severely resource challenged regions, with erratic limited electrical power no access dry ice. Intellectual Ventures Laboratory/Global Good modified Arktek passive storage...
Abstract Several approaches have produced an effective vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the influence of immune responses induced by other vaccinations on durability and efficacy response to SARS-CoV-2 is still unknown. We developed a hybrid for influenza viruses using virus-like particles (VLP) incorporated protein transfer with glycosylphosphatidylinositol (GPI)-anchored S1 RBD fused GM-CSF as adjuvant. GPI-RBD-GM-CSF fusion was...
Background: Chronic neurologic diseases are common sequelae of COVID. They severely impact the quality life and increase burden on healthcare systems. The long COVID neurological symptoms due to robust replication SARS-CoV-2 in nasal neuroepithelial cells, leading neuroinvasion inflammation central nerve system (CNS). Currently used medications vaccines do not inhibit epithelial cells. EGCG-palmitate (EC16), a multifunctional compound, has potential become novel intranasal-delivered drug for...
In responding to the demand for vaccine outreach solutions in remote off-grid areas developing countries, Intellectual Ventures Global Good developed a highly-efficient storage and PCM (Phase Change Material) freezing device prototype, called Arktek SDD (Solar Direct Drive). A final design product, which may differ certain details from will be by Good's commercial partner Aucma, leading manufacturer of refrigeration cold chain equipment. The prototype consists two parts: cooling system as an...
Abstract Several approaches have produced an effective vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the influence of immunity other vaccinations on durability and efficacy immune response SARS-CoV-2 is still unknown in settings where vaccines viruses need to be administered simultaneously. This will important factor developing multivalent seasonal viruses. We developed a hybrid for influenza using virus-like particles (VLP) incorporated with...
ABSTRACT The Coronavirus disease 2019 (COVID19) pandemic caused by Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is an ongoing threat to global public health. To this end, intense efforts are underway develop reagents aid in diagnostics, enhance preventative measures, and provide therapeutics for managing COVID-19. recent emergence of SARS-CoV-2 Omicron variants with enhanced transmissibility, altered antigenicity, significant escape existing monoclonal antibodies vaccines...